Physician profile
Ryan Michael Dauer
NPI 1376938449
$6,416.03
in general payments reported to CMS, 2019-2025
31 companies · $2,155 in 2025
The $2,155 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.33 · 2021: $20.03 · 2022: $811 · 2023: $1,706 · 2024: $1,696 · 2025: $2,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,519 · Education: $38.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,518.72 |
| Education | $38.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,044.44 | 2020-2025 | Rinvoq, Viberzi, Linzess |
| Janssen Biotech, INC. | $917.08 | 2022-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $804.92 | 2022-2025 | |
| Qol Medical, LLC | $580.32 | 2022-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $320.46 | 2023-2025 | Omvoh, Mounjaro |
| Celgene Corporation | $301.07 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $273.97 | 2022-2025 | Eohilia, Entyvio, Gattex |
| Boston Scientific Corporation | $271.17 | 2022-2025 | Spyglass, Axonics |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.39 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Celltrion USA INC. | $243.20 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $177.67 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $161.38 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $155.14 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $137.26 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $117.40 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $97.78 | 2024-2025 | Pancreaze, Qsymia |
| Phathom Pharmaceuticals, INC. | $91.88 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $88.88 | 2025 | Rezdiffra |
| Pfizer INC. | $68.06 | 2023 | |
| Braintree Laboratories, INC. | $58.11 | 2022-2025 | Suflave, Sutab |
| Medtronic, INC. | $44.09 | 2023 | Endoflip |
| Ironwood Pharmaceuticals, INC | $34.24 | 2023 | Linzess |
| Novo Nordisk INC | $31.19 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $26.15 | 2023 | Bylvay |
| Merck Sharp & Dohme LLC | $23.01 | 2022 | |
| Janssen Scientific Affairs, LLC | $22.08 | 2025 | Tremfya |
| Mahana Therapeutics, INC. | $20.98 | 2022 | |
| Endo Pharmaceuticals INC. | $16.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.33 | 2023 | Zeposia |
| Evoke Pharma, INC. | $13.98 | 2024 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Dauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.